FORGOTTEN HISTORY: Bntx | History Defined

BioNTech Moved Higher as the Broader Biotech Sector Hit a Post-Pandemic Peak, but BNTX Stock Needs Stronger Fundamentals to Keep Climbing

BioNTech shares moved higher as the broader biotech sector reached a post-pandemic peak, lifted by positive late-stage cancer vaccine data from peers rather than new clinical results of its own.

Barchart · Aug 24

BioNTech Maps Oncology Push, $1B Buyback and Manufacturing Cuts at AGM

BioNTech (NASDAQ:BNTX) used its virtual annual general meeting to outline a transition year marked by leadership changes, continued investment in oncology, a planned share repurchase program and a restructuring of its manufacturing network. Chairman of the Supervisory Board Helmut Jeggle said the 2

MarketBeat · May 15

BNTX Stock News: BioNTech Announces Layoffs as Covid-19 Revenue Slides

BioNTech shares sank yesterday as disappointing Q1 results prompted layoffs. But long-term investors still have ample reasons to load up on BNTX stock today.

Barchart · May 6

BioNTech Sees Higher 2025 Sales Driven By Bristol Myers Partnership

BioNTech SE (NASDAQ:BNTX) reported a third-quarter per-share loss of 14 cents (12 cents in euros) on Monday, a turnaround from earnings of 81 cents reported a year ago, missing the consensus earnings of 75 cents per share.

Benzinga · Nov 3, 2025

Pfizer, Moderna, BioNTech Stocks Tumble After Report Of Plan To Link COVID Vaccines To Child Deaths

Shares of COVID-19 vaccine makers Pfizer Inc (NYSE:PFE), BioNTech SE ADR (NASDAQ:BNTX) and Moderna Inc (NASDAQ:MRNA) are trading lower Friday following a Washington Post report that Trump administration health officials intend to link the vaccines to 25 child deaths. This assertion is reportedly based on unverified submissions to the Vaccine…

Benzinga · Sep 12, 2025

Pfizer, BioNTech Roll Out COVID-19 Update That Boosts Antibodies 4-Fold In High-Risk Adults

Pfizer Inc. (NYSE:PFE) and BioNTech SE (NASDAQ:BNTX) reported topline Phase 3 results for their LP.8.1-adapted monovalent COMIRNATY (2025-2026 Formula) in high-risk adults.

Benzinga · Sep 8, 2025

BioNTech, Bristol Myers Squibb Show Tumor Shrinkage In Lung Cancer Immunotherapy

BioNTech SE (NASDAQ:BNTX) and Bristol Myers Squibb Co (NYSE:BMY) shared interim Phase 2 data on pumitamig (BNT327/BMS986545) plus chemotherapy in patients with untreated extensive-stage small cell lung cancer (ES-SCLC).

Benzinga · Sep 8, 2025

BioNTech Advances On Positive Phase 3 Breast Cancer Drug Data

On Friday, BioNTech SE (NASDAQ:BNTX) and its partner Duality Biologics (Suzhou) Co., Ltd. released topline data from a Phase 3 trial in China evaluating trastuzumab pamirtecan (BNT323/DB-1303) versus trastuzumab emtansine (T-DM1) for HER2-positive unresectable or metastatic breast cancer patients who have previously received trastuzumab and a taxane-based chemotherapy.

Benzinga · Sep 5, 2025

Trump Administration Plans To Pull COVID-19 Vaccines Off Market 'Within Months'

The Trump administration is preparing to remove COVID-19 vaccines from the U.S. market "within months," according to a close associate of Health and Human Services Secretary Robert F. Kennedy Jr.

Benzinga · Aug 25, 2025

These Analysts Revise Their Forecasts On BioNTech After Q2 Results

BioNTech SE (NASDAQ:BNTX) reported a narrower loss for the second quarter on Monday.

Benzinga · Aug 5, 2025